Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepidoglyphus destructor extract histamine equivalent prick testing
2023-509541-13-00Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lepidoglyphus destructor extract in Lepidoglyphus destructor allergy, sponsored by Inmunotek. Primary endpoint: Histamine-equivalent concentration of Lepidoglyphus destructor extract. Started Aug 2024; status: completed.
02
Drugs
lepidoglyphus destructor extract
03
Conditions
Lepidoglyphus destructor allergy
Beyond the preview
Go deeper on 2023-509541-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509541-13-00.